Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
<strong>Background: </strong>Cardiovascular safety concerns for major cardiovascular events (MACE) were raised during the clinical trials of romosozumab. We aimed to evaluate the cardiovascular safety profile of romosozumab in a large pharmacovigilance database. <b>Methods:</b&g...
Main Authors: | Annika Vestergaard Kvist, Junaid Faruque, Enriqueta Vallejo-Yagüe, Stefan Weiler, Elizabeth M. Winter, Andrea M. Burden |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/8/1660 |
Similar Items
-
Romosozumab and cardiovascular safety in Japan
by: Yasuhiro Takeuchi
Published: (2021-09-01) -
Profile of romosozumab and its potential in the management of osteoporosis
by: Lim SY, et al.
Published: (2017-04-01) -
Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis
by: Toshihiro eSugiyama, et al.
Published: (2015-04-01) -
Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab
by: Jacqueline So, et al.
Published: (2020-12-01) -
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
by: Brown, J.P, et al.
Published: (2022)